다시 보는 알츠하이머병의 아밀로이드 가설 = Amyloid Theory of Alzheimer’s Disease Revisited

다국어 초록 (Multilingual Abstract)

Alzheimer’s disease(AD) is one of the most common causes of degenerative dementia in the elderly, and is characterized by a progressive deterioration of memory and other higher cognitive functions. Amyloid plaque is observed in the brains of patients with AD and has received attention as a pathognomonic feature since the disease was first reported. The amyloid hypothesis proposes that the toxic accumulation of amyloid-β protein plays a dominant role in the development and progression of AD. Since this theory was first presented in the early 1990s, it has influenced the development of biomarkers for the earlier detection of AD and research to find new treatments. However, recent reports have shown that amyloid deposits are commonly observed in cognitively normal aged persons, and therapeutic agents that effectively reduce the concentration of amyloid-beta in the brains of AD patients have not been effective at improving either cognitive function or the activities of daily living. This suggests that we need to consider alternative theories for AD other than the amyloid hypothesis. This review focuses on the amyloid hypothesis, with details on the production, metabolism, and clearance of amyloid-beta, and on recent advances in the development of therapeutic agents based on this hypothesis.

목차 (Table of Contents)

• 서론
• 본론
• 결론
• 참고문헌

참고문헌 (Reference)

1 Wolfe MS, "gamma-Secretase inhibitors and modulators for Alzheimer’s disease" 120 (120): 89-98, 2012

2 Busciglio J, "beta-amyloid fibrils induce tau phosphorylation and loss of microtubule binding" 14 : 879-888, 1995

3 Rodrigue KM, "beta-Amyloid burden in healthy aging : regional distribution and cognitive consequences" 78 : 387-395, 2012

4 Lichtenthaler SF, "alpha-secretase in Alzheimer’s disease: molecular identity, regulation and therapeutic potential" 116 : 10-21, 2011

5 Iwatsubo T, "Visualization of A beta 42(43)and A beta 40 in senile plaques with end-specific A beta monoclonals : evidence that an initially deposited species is A beta 42(43)" 13 : 45-53, 1994

6 Salloway S, "Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer’s Disease" 370 : 322-333, 2014

7 Bell RD, "Transport pathways for clearance of human Alzheimer’s amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system" 27 : 909-918, 2007

8 Schwab C, "Transgenic mice overexpressing amyloid beta protein are an incomplete model of Alzheimer disease" 188 : 52-64, 2004

9 Aisen PS, "Tramiprosate in mild-to-moderate Alzheimer’s disease - a randomized, double-blind, placebo-controlled, multi-centre study(the Alphase Study)" 7 : 102-111, 2011

10 Imbimbo BP, "Therapeutic potential of gamma-secretase inhibitors and modulators" 8 : 54-61, 2008

11 Etcheberrigaray R, "Therapeutic effects of PKC activators in Alzheimer’s disease transgenic mice" 101 : 11141-11146, 2004

12 Armstrong RA, "The spatial patterns of plaques and tangles in Alzheimer’s disease do not support the ‘cascade hypothesis’" 4 : 16-20, 1993

13 Verdile G, "The role of beta amyloid in Alzheimer’s disease: still a cause of everything or the only one who got caught?" 50 : 397-409, 2004

14 McGeer PL, "The possible role of complement activation in Alzheimer disease" 8 : 519-523, 2002

15 Godbolt AK, "The natural history of Alzheimer disease : a longitudinal presymptomatic and symptomatic study of a familial cohort" 61 : 1743-1748, 2004

16 Chavez-Gutierrez L, "The mechanism of gamma-Secretase dysfunction in familial Alzheimer disease" 31 : 2261-2274, 2012

17 Holmes C, "The clinical phenotype of familial and sporadic late onset Alzheimer’s disease" 17 : 146-149, 2002

18 Hardy J, "The amyloid hypothesis of Alzheimer’s disease : progress and problems on the road to therapeutics" 297 : 353-356, 2002

19 Karran E, "The amyloid cascade hypothesis for Alzheimer’s disease : an appraisal for the development of therapeutics" 10 : 698-712, 2011

20 Braak H, "Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry" 112 : 389-404, 2006

21 Notkola IL, "Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer’s disease" 17 : 14-20, 1998

22 Goate A, "Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer’s disease" 349 : 704-706, 1991

23 Winblad B, "Safety, tolerability, and antibody response of active Abeta immunotherapy with CAD106 in patients with Alzheimer’s disease: randomised, double-blind, placebo-controlled, first-in-human study" 11 : 597-604, 2012

24 Lannfelt L, "Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer’s disease: a phase IIa, double-blind, randomised, placebo-controlled trial" 7 : 779-786, 2008

25 Farlow M, "Safety and biomarker effects of solanezumab in patients with Alzheimer’s disease" 8 : 261-271, 2012

26 Gold M, "Rosiglitazone monotherapy in mild-to-moderate Alzheimer’s disease: results from a randomized, double-blind, placebo-controlled phase III study" 30 : 131-146, 2010

27 Roberson ED, "Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer’s disease mouse model" 316 : 750-754, 2007

28 Hemming ML, "Reducing amyloid plaque burden via ex vivo gene delivery of an Abeta-degrading protease: a novel therapeutic approach to Alzheimer disease" 4 : e262-, 2007

29 Edbauer D, "Reconstitution of gamma-secretase activity" 5 : 486-488, 2003

30 Garai K, "Quantitative analysis of the time course of Abeta oligomerization and subsequent growth steps using tetramethylrhodamine-labeled Abeta" 110 : 3321-3326, 2013

31 Saido T, "Proteolytic degradation of amyloid beta-protein" 2 : a006379-, 2012

32 Frisoni GB, "Primary or secondary prevention for AD: who cares?" 11 (11): 567-, 2012

33 Iwata N, "Presynaptic localization of neprilysin contributes to efficient clearance of amyloid-beta peptide in mouse brain" 24 : 991-998, 2004

34 Armstrong RA, "Plaques and tangles and the pathogenesis of Alzheimer’s disease" 44 : 1-11, 2006

35 Doody RS, "Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer’s Disease" 370 : 311-321, 2014

36 Lanz TA, "Pharmacodynamics and pharmacokinetics of the gamma-secretase inhibitor PF-3084014" 334 : 269-277, 2010

37 Fiala M, "Phagocytosis of amyloid-beta and inflammation : two faces of innate immunity in Alzheimer’s disease" 11 : 457-463, 2007

38 Lannfelt L, "Perspectives on future Alzheimer therapies : amyloid-beta protofibrils-a new target for immunotherapy with BAN2401 in Alzheimer’s disease" 6 : 16-, 2014

39 Bard F, "Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease" 6 : 916-919, 2000

40 Landreth G, "PPARgamma agonists as therapeutics for the treatment of Alzheimer’s disease" 5 : 481-489, 2008

41 Faux NG, "PBT2 rapidly improves cognition in Alzheimer’s Disease : additional phase II analyses" 20 : 509-516, 2010

42 Selkoe D, "Notch and Presenilin : regulated intramembrane proteolysis links development and degeneration" 26 : 565-597, 2003

43 Zago W, "Neutralization of soluble, synaptotoxic amyloid beta species by antibodies is epitope specific" 32 : 2696-2702, 2012

44 Nicoll JA, "Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide : a case report" 9 : 448-452, 2003

45 Braak H, "Neuropathological stageing of Alzheimer-related changes" 82 : 239-259, 1991

46 Gomez-Isla T, "Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer’s disease" 41 : 17-24, 1997

47 Cleary JP, "Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function" 8 : 79-84, 2005

48 Sawamura N, "Modulation of amyloid precursor protein cleavage by cellular sphingolipids" 279 : 11984-11991, 2004

49 Okello A, "Microglial activation and amyloid deposition in mild cognitive impairment : a PET study" 72 : 56-62, 2009

50 Yan R, "Membrane-anchored aspartyl protease with Alzheimer’s disease beta-secretase activity" 402 : 533-537, 1999

51 Ostrowitzki S, "Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab" 69 : 198-207, 2012

52 Yoon IS, "Low-density lipoprotein receptor-related protein promotes amyloid precursor protein trafficking to lipid rafts in the endocytic pathway" 21 : 2742-2752, 2007

53 Sagare AP, "Low-density lipoprotein receptor-related protein 1 : a physiological Abeta homeostatic mechanism with multiple therapeutic opportunities" 136 : 94-105, 2012

54 Kojro E, "Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha-secretase ADAM 10" 98 : 5815-5820, 2001

55 Farris W, "Loss of neprilysin function promotes amyloid plaque formation and causes cerebral amyloid angiopathy" 171 : 241-251, 2007

56 Duyckaerts C, "Looking for the link between plaques and tangles" 25 : 735-739, 2004

57 Holmes C, "Long-term effects of Abeta42 immunisation in Alzheimer’s disease: follow-up of a randomised, placebo-controlled phase I trial" 372 : 216-223, 2008

58 Tokuda T, "Lipidation of apolipoprotein E influences its isoform-specific interaction with Alzheimer’s amyloid beta peptides" 2 : 359-365, 2000

59 Huttunen HJ, "Knockdown of ACAT-1 reduces amyloidogenic processing of APP" 581 : 1688-1692, 2007

60 Perez M, "Interaction of Alzheimer’s disease amyloid beta peptide fragment 25-35 with tau protein, and with a tau peptide containing the microtubule binding domain" 6 : 461-467, 2004

61 Schaeffer EL, "Insights into Alzheimer disease pathogenesis from studies in transgenic animal models" 66 (66): 45-54, 2011

62 Huttunen HJ, "Inhibition of acyl-coenzyme A : cholesterol acyl transferase modulates amyloid precursor protein trafficking in the early secretory pathway" 23 : 3819-3828, 2009

63 Rowe CC, "Imaging beta-amyloid burden in aging and dementia" 68 : 1718-1725, 2007

64 Bohrmann B, "Gantenerumab : a novel human anti-Abeta antibody demonstrates sustained cerebral amyloid-beta binding and elicits cell-mediated removal of human amyloid-beta" 28 : 49-69, 2012

65 Snow AD, "Exebryl-1: A novel small molecule currently in human clinical trials as a disease-modifying drug for the treatment of Alzheimer’s disease" 5 : 418-, 2009

66 Marcade M, "Etazolate, a neuroprotective drug linking GABA(A) receptor pharmacology to amyloid precursor protein processing" 106 : 392-404, 2008

67 Bard F, "Epitope and isotype specificities of antibodies to beta-amyloid peptide for protection against Alzheimer’s disease-like neuropathology" 100 : 2023-2028, 2003

68 Leissring MA, "Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death" 40 : 1087-1093, 2003

69 Griffiths HH, "Emerging and potential therapies for Alzheimer’s disease" 12 : 693-704, 2008

70 Panza F, "Efficacy and safety studies of gantenerumab in patients with Alzheimer’s disease" 1-14, 2014

71 Fox NC, "Effects of Abeta immunization(AN1792)on MRI measures of cerebral volume in Alzheimer disease" 64 : 1563-1572, 2005

72 Green RC, "Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease : a randomized controlled trial" 302 : 2557-2564, 2009

73 Vellas B, "EHT0202 in Alzheimer’s disease: a 3-month, randomized, placebo-controlled, double-blind study" 8 : 203-212, 2011

74 Osenkowski P, "Direct and potent regulation of gamma-secretase by its lipid microenvironment" 283 : 22529-22540, 2008

75 Schneeberger A, "Development of AFFITOPE vaccines for Alzheimer’s disease(AD)--from concept to clinical testing" 13 : 264-267, 2009

76 Tesseur I, "Deficiency in neuronal TGF-beta signaling promotes neurodegeneration and Alzheimer’s pathology" 116 : 3060-3069, 2006

77 Wolozin B, "Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors" 57 : 1439-1443, 2000

78 Mawuenyega KG, "Decreased clearance of CNS beta-amyloid in Alzheimer’s disease" 330 : 1774-, 2010

79 McLaurin J, "Cyclohexanehexol inhibitors of Abeta aggregation prevent and reverse Alzheimer phenotype in a mouse model" 12 : 801-808, 2006

80 Okello A, "Conversion of amyloid positive and negative MCI to AD over 3 years : an 11C-PIB PET study" 73 : 754-760, 2009

81 Medeiros R, "Connecting TNF-alpha signaling pathways to iNOS expression in a mouse model of Alzheimer’s disease : relevance for the behavioral and synaptic deficits induced by amyloid beta protein" 27 : 5394-5404, 2007

82 Rogers J, "Complement activation by beta-amyloid in Alzheimer disease" 89 : 10016-10020, 1992

83 Rogers J, "Complement activation and beta-amyloid-mediated neurotoxicity in Alzheimer’s disease" 143 : 624-630, 1992

84 Kayed R, "Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis" 300 : 486-489, 2003

85 DeMattos RB, "Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer’s disease" 99 : 10843-10848, 2002

86 Gilman S, "Clinical effects of Abeta immunization(AN1792)in patients with AD in an interrupted trial" 64 : 1553-1562, 2005

87 Selkoe DJ, "Clearing the brain’s amyloid cobwebs" 32 : 177-180, 2001

88 Shibata M, "Clearance of Alzheimer’s amyloidss(1-40)peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier" 106 : 1489-1499, 2000

89 Wahrle S, "Cholesterol-dependent gamma-secretase activity in buoyant cholesterol-rich membrane microdomains" 9 : 11-23, 2002

90 Zlokovic BV, "Cerebrovascular effects of apolipoprotein E : implications for Alzheimer disease" 70 : 440-444, 2013

91 Mandel SA, "Cell signaling pathways and iron chelation in the neurorestorative activity of green tea polyphenols : special reference to epigallocatechin gallate(EGCG)" 15 : 211-222, 2008

92 Imbimbo BP, "CHF5074, a novel gamma-secretase modulator, attenuates brain beta-amyloid pathology and learning deficit in a mouse model of Alzheimer’s disease" 156 : 982-993, 2009

93 Town T, "Blocking TGF-beta-Smad2/3 innate immune signaling mitigates Alzheimer-like pathology" 14 : 681-687, 2008

94 Buttini M, "Beta-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer’s disease" 25 : 9096-9101, 2005

95 Martone RL, "Begacestat(GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer’s disease" 331 : 598-608, 2009

96 Holtzman DM, "Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer’s disease" 97 : 2892-2897, 2000

97 Ryan JM, "Anti-amyloid-beta immunotherapy in Alzheimer’s disease : ACC-001 clinical trials are ongoing" 17 : 243-, 2009

98 Adolfsson O, "An effector-reduced anti-beta-amyloid(Abeta)antibody with unique abeta binding properties promotes neuroprotection and glial engulfment of Abeta" 32 : 9677-9689, 2012

99 Ehehalt R, "Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts" 160 : 113-123, 2003

100 Lannfelt L, "Amyloid-ß-directed immunotherapy for Alzheimer’s disease" 275 : 284-295, 2014

101 Sperling R, "Amyloid-related imaging abnormalities in patients with Alzheimer’s disease treated with bapineuzumab : a retrospective analysis" 11 : 241-249, 2012

102 Shankar GM, "Amyloid-beta protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory" 14 : 837-842, 2008

103 Schenk D., "Amyloid-beta immunotherapy for Alzheimer’s disease : the end of the beginning" 3 : 824-828, 2002

104 Rabinovici GD, "Amyloid imaging in aging and dementia : testing the amyloid hypothesis in vivo" 21 : 117-128, 2009

105 Selkoe DJ, "Alzheimer’s disease: genotypes, phenotypes, and treatments" 275 : 630-631, 1997

106 Zigman WB, "Alzheimer’s disease in Down syndrome : neurobiology and risk" 13 : 237-246, 2007

107 Hardy JA, "Alzheimer’s disease : the amyloid cascade hypothesis" 256 : 184-185, 1992

108 Selkoe DJ, "Alzheimer’s disease : molecular understanding predicts amyloid-based therapeutics" 43 : 545-584, 2003

109 Doody RS, "Alzheimer’s Disease Cooperative Study Data A, Publication C. Phase 3 trials of solanezumab and bapineuzumab for Alzheimer’s disease" 370 : 1460-, 2014

110 Puglielli L, "Acyl-coenzyme A : cholesterol acyltransferase modulates the generation of the amyloid beta-peptide" 3 : 905-912, 2001

111 Irizarry MC, "APPSw transgenic mice develop age-related A beta deposits and neuropil abnormalities, but no neuronal loss in CA1" 56 : 965-973, 1997

112 Doody RS, "A phase 3 trial of semagacestat for treatment of Alzheimer’s disease" 369 : 341-350, 2013

113 Salloway S, "A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease" 77 : 1253-1262, 2011

114 Salloway S, "A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease" 73 : 2061-2070, 2009

115 Aisen PS, "A Phase II study targeting amyloidbeta with 3APS in mild-to-moderate Alzheimer disease" 67 : 1757-1763, 2006

116 Doody RS, "A Phase 3 Trial of Semagacestat for Treatment of Alzheimer’s Disease" 369 : 341-350, 2013